Enanta Pharmaceuticals | ENTA - Kısa Vadeli Yükümlülükler





Kısa Vadeli Yükümlülükler Değişiklik Tarih
AbbVie USD 43.1B 1.46B 2026-09
Amgen USD 23.23B 2.27B 2026-09
Anika Therapeutics USD 22.15M 1.18M 2026-06
Arrowhead Research USD 283.35M 11.87M 2026-06
AstraZeneca USD 31.27B 286M 2026-09
BioCryst Pharmaceuticals USD 195.83M 13.02M 2026-09
Biogen USD 3.9B 18.7M 2026-09
Bristol-Myers Squibb USD 18.75B 94M 2026-09
Enanta Pharmaceuticals USD 44.73M 3.83M 2025-12
Gilead Sciences USD 12B 982M 2026-09
GlaxoSmithKline GBP 20.72B 814M 2026-09
Halozyme Therapeutics USD 476.09M 131.65M 2026-09
Heron Therapeutics USD 92.14M 1.63M 2026-06
Immunic USD 38.36M 7.74M 2026-03
Incyte USD 1.44B 125.72M 2026-09
Insmed USD 596.57M 157.83M 2026-09
Ionis Pharmaceuticals USD 315.64M 401.36M 2026-06
J&J USD 55.46B 562M 2026-09
Karyopharm Therapeutics USD 117.3M 25.24M 2026-03
Ligand Pharmaceuticals USD 500.57M 453.83M 2026-09
Merck USD 28.8B 1.07B 2026-09
Neurocrine Biosciences USD 984.6M 110.1M 2026-09
Novartis USD 32.52B 777M 2026-09
Novavax USD 329.84M 729K 2026-09
Pfizer USD 31.73B 920M 2026-09
PTC Therapeutics USD 776.08M 5.01M 2026-09
Roche Holding CHF 28.85B 846M 2026-06
Sarepta Therapeutics USD 656.35M 153.44M 2026-09
Vertex Pharmaceuticals USD 5B 1.06B 2026-09